We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exploring Analyst Estimates for Alkermes (ALKS) Q4 Earnings, Beyond Revenue and EPS
Read MoreHide Full Article
Wall Street analysts expect Alkermes (ALKS - Free Report) to post quarterly earnings of $0.43 per share in its upcoming report, which indicates a year-over-year increase of 207.1%. Revenues are expected to be $361.24 million, up 18.6% from the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 2.5% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
With that in mind, let's delve into the average projections of some Alkermes metrics that are commonly tracked and projected by analysts on Wall Street.
The consensus among analysts is that 'Revenues- Product sales, net' will reach $241.44 million. The estimate indicates a change of +11.7% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Revenues- Manufacturing and Royalty revenues' of $123.97 million. The estimate indicates a change of +40% from the prior-year quarter.
Analysts predict that the 'Revenues- Key Commercial Product Revenues- ARISTADA' will reach $84.08 million. The estimate points to a change of +6.1% from the year-ago quarter.
The average prediction of analysts places 'Revenues- Key Commercial Product Revenues- VIVITROL' at $101.94 million. The estimate points to a change of 0% from the year-ago quarter.
Alkermes shares have witnessed a change of -3.1% in the past month, in contrast to the Zacks S&P 500 composite's +5.8% move. With a Zacks Rank #3 (Hold), ALKS is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Exploring Analyst Estimates for Alkermes (ALKS) Q4 Earnings, Beyond Revenue and EPS
Wall Street analysts expect Alkermes (ALKS - Free Report) to post quarterly earnings of $0.43 per share in its upcoming report, which indicates a year-over-year increase of 207.1%. Revenues are expected to be $361.24 million, up 18.6% from the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 2.5% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
With that in mind, let's delve into the average projections of some Alkermes metrics that are commonly tracked and projected by analysts on Wall Street.
The consensus among analysts is that 'Revenues- Product sales, net' will reach $241.44 million. The estimate indicates a change of +11.7% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Revenues- Manufacturing and Royalty revenues' of $123.97 million. The estimate indicates a change of +40% from the prior-year quarter.
Analysts predict that the 'Revenues- Key Commercial Product Revenues- ARISTADA' will reach $84.08 million. The estimate points to a change of +6.1% from the year-ago quarter.
The average prediction of analysts places 'Revenues- Key Commercial Product Revenues- VIVITROL' at $101.94 million. The estimate points to a change of 0% from the year-ago quarter.
View all Key Company Metrics for Alkermes here>>>
Alkermes shares have witnessed a change of -3.1% in the past month, in contrast to the Zacks S&P 500 composite's +5.8% move. With a Zacks Rank #3 (Hold), ALKS is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>